Ali Habib, MD, neuromuscular specialist at UCI Health, explains the rationale behind cemdisiran's liver-directed RNA interference approach and how it differs from established C5 inhibition strategies in generalized myasthenia gravis.
Exploring Cemdisiran and the Evolving Treatment Landscape in Myasthenia Gravis
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
2
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
3
NeurologyLive® Brain Games: November 1, 2026
4
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
5